AU707779C - Substituted liposaccharides useful in the treatment and prevention of endotoxemia - Google Patents

Substituted liposaccharides useful in the treatment and prevention of endotoxemia

Info

Publication number
AU707779C
AU707779C AU63802/96A AU6380296A AU707779C AU 707779 C AU707779 C AU 707779C AU 63802/96 A AU63802/96 A AU 63802/96A AU 6380296 A AU6380296 A AU 6380296A AU 707779 C AU707779 C AU 707779C
Authority
AU
Australia
Prior art keywords
alkyl
branched
straight
compound
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU63802/96A
Other languages
English (en)
Other versions
AU707779B2 (en
AU6380296A (en
Inventor
William J Christ
Tsutomu Kawata
Seiichi Kobayashi
Daniel P Rossignol
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Original Assignee
Eisai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23833509&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU707779(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eisai Co Ltd filed Critical Eisai Co Ltd
Publication of AU6380296A publication Critical patent/AU6380296A/en
Application granted granted Critical
Publication of AU707779B2 publication Critical patent/AU707779B2/en
Publication of AU707779C publication Critical patent/AU707779C/en
Assigned to EISAI R&D MANAGEMENT CO., LTD. reassignment EISAI R&D MANAGEMENT CO., LTD. Alteration of Name(s) in Register under S187 Assignors: EISAI CO. LTD.
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
    • C07H5/04—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H11/00—Compounds containing saccharide radicals esterified by inorganic acids; Metal salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/12—Acyclic radicals, not substituted by cyclic structures attached to a nitrogen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/04—Disaccharides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
AU63802/96A 1995-06-05 1996-06-05 Substituted liposaccharides useful in the treatment and prevention of endotoxemia Expired AU707779C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/461,675 US5750664A (en) 1995-06-05 1995-06-05 Substituted liposaccharides useful in the treatment and prevention of endotoxemia
US08/461675 1995-06-05
PCT/US1996/009578 WO1996039411A1 (en) 1995-06-05 1996-06-05 Substituted liposaccharides useful in the treatment and prevention of endotoxemia

Publications (3)

Publication Number Publication Date
AU6380296A AU6380296A (en) 1996-12-24
AU707779B2 AU707779B2 (en) 1999-07-22
AU707779C true AU707779C (en) 2001-12-06

Family

ID=23833509

Family Applications (1)

Application Number Title Priority Date Filing Date
AU63802/96A Expired AU707779C (en) 1995-06-05 1996-06-05 Substituted liposaccharides useful in the treatment and prevention of endotoxemia

Country Status (21)

Country Link
US (8) US5750664A (enExample)
EP (1) EP0853627B1 (enExample)
JP (3) JP4009318B2 (enExample)
KR (1) KR100416335B1 (enExample)
CN (1) CN1067082C (enExample)
AT (1) ATE258185T1 (enExample)
AU (1) AU707779C (enExample)
CA (1) CA2223140C (enExample)
DE (1) DE69631376T2 (enExample)
DK (1) DK0853627T3 (enExample)
ES (1) ES2214543T3 (enExample)
HU (1) HU221342B1 (enExample)
IL (2) IL122251A0 (enExample)
MX (1) MX9709502A (enExample)
NO (1) NO310239B1 (enExample)
NZ (1) NZ312299A (enExample)
PT (1) PT853627E (enExample)
RU (1) RU2170738C2 (enExample)
TW (1) TW366345B (enExample)
WO (1) WO1996039411A1 (enExample)
ZA (1) ZA964666B (enExample)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6417172B1 (en) * 1995-06-05 2002-07-09 Eisai Co., Ltd. Prevention and treatment of pulmonary bacterial infection or symptomatic pulmonary exposure to endotoxin by inhalation of antiendotoxin drugs
US5750664A (en) * 1995-06-05 1998-05-12 Eisai Co., Ltd. Substituted liposaccharides useful in the treatment and prevention of endotoxemia
US6235724B1 (en) * 1996-07-03 2001-05-22 Eisai Co., Ltd. Injections containing lipid a analogues and process for the preparation thereof
JP3943334B2 (ja) 1998-09-01 2007-07-11 エーザイ・アール・アンド・ディー・マネジメント株式会社 リピッドａ類縁体含有注射剤の評価方法
US20030130212A1 (en) * 1999-01-14 2003-07-10 Rossignol Daniel P. Administration of an anti-endotoxin drug by intravenous infusion
DE60036790T2 (de) * 1999-01-14 2008-07-24 Eisai R&D Management Co., Ltd. Verwendung von e5564 zur behandlung von sepsis durch intravenöse infusion
US6835721B2 (en) 1999-02-01 2004-12-28 Eisai Co., Ltd. Immunomodulatory compounds and methods of use thereof
US7915238B2 (en) * 1999-02-01 2011-03-29 Eisai R & D Management Co., Ltd. Immunomodulatory compounds and methods of use thereof
US20040006242A1 (en) * 1999-02-01 2004-01-08 Hawkins Lynn D. Immunomodulatory compounds and method of use thereof
CZ20012919A3 (cs) * 1999-02-10 2002-03-13 Sankyo Company, Limited Analogy etherového typu lipidu A 1-karboxylové kyseliny
US20040127456A1 (en) * 2000-01-14 2004-07-01 Melvyn Lynn Prevention and treatment of endotoxemia and related complications associated with surgery
US20050101549A1 (en) * 2000-01-14 2005-05-12 Melvyn Lynn Prevention and treatment of endotoxemia and related complications associated with surgery
US6906042B2 (en) * 2000-02-18 2005-06-14 Eisai Co., Ltd. Micelles
US6861512B2 (en) * 2000-03-01 2005-03-01 Eisai Co., Ltd. Separation of olefinic isomers
AU2001275520A1 (en) * 2000-06-09 2001-12-17 Eisai Co. Ltd. Administration of an anti-endotoxin drug by bolus or intermittent intravenous infusion
US20030105033A1 (en) * 2000-06-09 2003-06-05 Rossignol Daniel P. Administration of an anti-endotoxin drug by bolus or intermittent intravenous infusion
WO2002088072A1 (en) * 2001-04-23 2002-11-07 Eisai Co., Ltd. Process for preparation of alkylene compounds
WO2002088062A1 (en) * 2001-04-23 2002-11-07 Eisai Co., Ltd. Process for preparation of alcohol derivatives
US20040198652A1 (en) * 2001-04-24 2004-10-07 Carter J. Paul Methods and compositions for preventing and treating septic shock and endotoxemia
WO2002094019A1 (en) * 2001-05-22 2002-11-28 Eisai Co., Ltd Highly purified antiendotoxin compound
DE10125179A1 (de) * 2001-05-23 2002-12-05 Laves Ralph Georg Verwendung von LPS zur Behandlung intestinaler Entzündungsprozesse
US7727974B2 (en) * 2001-08-10 2010-06-01 Eisai R & D Management Co., Ltd. Methods of reducing the severity of mucositis
EP2338497A1 (en) 2001-08-10 2011-06-29 Eisai R&D Management Co., Ltd. Treatment and prevention of heat shock protein-associated diseases and conditions
WO2003050137A2 (en) * 2001-12-11 2003-06-19 David Schwartz Toll-like receptor 4 mutations
AU2002950657A0 (en) * 2002-08-08 2002-09-12 Alchemia Limited Derivatives of monosaccharides for drug discovery
AU2002951995A0 (en) * 2002-10-11 2002-10-31 Alchemia Limited Classes of compounds that interact with gpcrs
WO2004058788A1 (ja) * 2002-12-24 2004-07-15 Sankyo Company, Limited 右糖グルコースリピドa類縁体
SI1589934T1 (sl) * 2003-01-06 2016-02-29 Corixa Corporation Corporation Service Company Določene aminoalkil glukozaminid fosfat spojine in njih uporaba
RU2346950C2 (ru) * 2003-01-28 2009-02-20 Академис Зикенхейс Лейден Пептидные ингибиторы токсинов, производные ll-37
WO2004074303A2 (en) * 2003-02-20 2004-09-02 Eisai Co, Ltd. Reagents and methods for preparing lps antagonist b1287 and stereoisomers thereof
CN1780824A (zh) * 2003-03-05 2006-05-31 卫材株式会社 预防和治疗内毒素相关疾病和病症的组合物和方法
WO2005027826A2 (en) * 2003-07-14 2005-03-31 Eisai, Co, Ltd. Methods and treating severe acute respiratory syndrome
WO2005072097A2 (en) 2003-12-16 2005-08-11 University Of Massachusetts Toll-like receptor 9 modulators
KR20060121293A (ko) * 2004-01-08 2006-11-28 상꾜 가부시키가이샤 좌당 글루코오스리피드ａ 유연체
US20070292418A1 (en) * 2005-04-26 2007-12-20 Eisai Co., Ltd. Compositions and methods for immunotherapy
CN101355928B (zh) 2005-04-26 2013-05-22 卫材R&D管理株式会社 用于癌症免疫疗法的组合物和方法
US20100015125A1 (en) * 2005-06-17 2010-01-21 University Of Rochester Methods and compositions for enhancing immune memory by blocking intrahepatic activated t cell deletion
WO2007026675A1 (ja) * 2005-08-31 2007-03-08 Eisai R & D Management Co., Ltd. リピッドａ類縁体の製造方法
JP5118968B2 (ja) * 2005-08-31 2013-01-16 エーザイ・アール・アンド・ディー・マネジメント株式会社 リピッドａ類縁体の製造方法
US7943588B2 (en) 2006-03-28 2011-05-17 Trustees Of Dartmouth College Method for preventing or treating neuropathic pain
WO2008059307A2 (en) * 2006-11-16 2008-05-22 Om Pharma Functionalized beta 1,6 glucosamine disaccharides and process for their preparation
CA2669674C (en) 2006-11-22 2016-05-17 Eisai R&D Management Co., Ltd. Sodium salt of disaccharide compound, method for producing the same, and use of the same
ES2392890T3 (es) * 2006-11-22 2012-12-14 Eisai R&D Management Co., Ltd. Sal sódica de un compuesto disacarídico, procedimiento para la producción de la misma y uso de la misma
AU2007323134B2 (en) 2006-11-23 2013-05-02 Cadila Pharmaceuticals Limited Poly-TLR antagonist
WO2011035026A1 (en) * 2009-09-16 2011-03-24 Heidi Ehrentraut Methods for treating myocardial disorders
WO2011038537A1 (zh) * 2009-09-29 2011-04-07 上海南方基因科技有限公司 败血症以及败血症休克的预测、预防和治疗方法及试剂盒
GB201013785D0 (en) 2010-08-17 2010-09-29 Ucl Business Plc Treatment
JP2012246470A (ja) 2011-05-31 2012-12-13 Sharp Corp 半導体ナノ粒子の製造方法、半導体ナノ粒子、ならびにこれを用いた蛍光体
HK1203474A1 (en) * 2011-12-22 2015-10-30 Nanoco Technologies Limited Surface modified nanoparticles
CA2868458A1 (en) 2012-03-28 2013-10-03 University Of Maryland, Baltimore Administration of eritoran or pharmaceutically acceptable salts thereof to treat orthomyxovirus infections
WO2014113048A1 (en) * 2013-01-18 2014-07-24 Loma Linda University Compositions and methods for diagnosing and treating sepsis
WO2015006740A2 (en) 2013-07-11 2015-01-15 Alnylam Pharmaceuticals, Inc. Oligonucleotide-ligand conjugates and process for their preparation
US9584991B1 (en) * 2014-06-19 2017-02-28 Isaac S. Daniel Method of communicating and accessing social networks using interactive coded messages
CN114712383B (zh) * 2016-03-30 2024-09-24 阿尤维斯研究有限公司 新组合物和治疗方法
EP3795576B1 (en) 2016-09-14 2023-06-07 Genomatica, Inc. 1,3-fatty diol compounds and glycosylated derivatives thereof
EP3512508B1 (en) * 2016-09-16 2022-03-16 Eisai R&D Management Co., Ltd. Method of use of eritoran as a tlr4 antagonist for treatment of ebola and marburg disease
AU2019400340A1 (en) * 2018-12-17 2021-05-20 Eisai R&D Management Co., Ltd. Formulation comprising liposomes
WO2021207218A1 (en) 2020-04-06 2021-10-14 Eisai R&D Management Co., Ltd. Treatment of nidovirales infection with eritoran
CN113527396B (zh) * 2020-04-17 2024-02-02 上海医药工业研究院 一种疫苗佐剂mpla的中间体、合成及应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4495346A (en) * 1981-03-30 1985-01-22 Wisconsin Alumni Research Foundation Method of preparing a disaccharide
US4987237A (en) * 1983-08-26 1991-01-22 Ribi Immunochem Research, Inc. Derivatives of monophosphoryl lipid A
JPS6153295A (ja) * 1984-08-24 1986-03-17 Dai Ichi Seiyaku Co Ltd ジサツカライド誘導体
US5066794A (en) * 1984-08-24 1991-11-19 Daiichi Pharmaceutical Co., Ltd. Process for preparing a disaccharide derivative
HU199494B (en) * 1985-06-28 1990-02-28 Sandoz Ag Process for producing new saccharides and pharmaceutical compositions comprising same
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5158939A (en) * 1989-07-21 1992-10-27 Wisconsin Alumni Research Foundation Method of stimulating the immune systems of animals and compositions useful therefor
JP2839916B2 (ja) * 1989-10-20 1998-12-24 三共株式会社 リピドａ３位エーテル類縁体
RU1836378C (ru) 1989-12-11 1993-08-23 Санкио Компани Лимитед Способ получени аналогов липида А
JP2847319B2 (ja) 1990-05-18 1999-01-20 イビデン株式会社 電子部品搭載用多層ボンディング基板
JP3040847B2 (ja) 1990-06-22 2000-05-15 三共株式会社 リピドｘ類縁体
AU660325B2 (en) * 1991-10-11 1995-06-22 Eisai Co. Ltd. Anti-endotoxin compounds and related molecules and methods
US5530113A (en) * 1991-10-11 1996-06-25 Eisai Co., Ltd. Anti-endotoxin compounds
JP3135990B2 (ja) 1992-07-31 2001-02-19 沖電気工業株式会社 パリティ付加回路
US5413785A (en) * 1993-01-27 1995-05-09 New England Deaconess Hospital Corp. Methodology employing lactobacillus GG for reduction of plasma endotoxin levels circulating in-vivo
PT729473E (pt) * 1993-11-17 2001-02-28 Deutsche Om Arzneimittel Gmbh Dissacaridos de glucosamina metodo para a sua preparacao composicao farmaceutica contendo os mesmos e sua utilizacao
US6417172B1 (en) * 1995-06-05 2002-07-09 Eisai Co., Ltd. Prevention and treatment of pulmonary bacterial infection or symptomatic pulmonary exposure to endotoxin by inhalation of antiendotoxin drugs
US5750664A (en) 1995-06-05 1998-05-12 Eisai Co., Ltd. Substituted liposaccharides useful in the treatment and prevention of endotoxemia
JP4235193B2 (ja) 2005-06-07 2009-03-11 日本電信電話株式会社 イベント履歴蓄積装置、イベント情報検証装置、イベント履歴蓄積方法、イベント情報検証方法およびイベント情報処理システム

Also Published As

Publication number Publication date
HUP9802662A3 (en) 1999-06-28
DK0853627T3 (da) 2004-06-01
CN1067082C (zh) 2001-06-13
EP0853627A1 (en) 1998-07-22
WO1996039411A1 (en) 1996-12-12
JP2011121970A (ja) 2011-06-23
DE69631376T2 (de) 2004-11-11
JP4712001B2 (ja) 2011-06-29
ATE258185T1 (de) 2004-02-15
ZA964666B (en) 1997-03-11
US7994154B2 (en) 2011-08-09
US20100227835A1 (en) 2010-09-09
PT853627E (pt) 2004-05-31
US5935938A (en) 1999-08-10
US7737129B2 (en) 2010-06-15
NO975644D0 (no) 1997-12-04
US20030144503A1 (en) 2003-07-31
JPH11506793A (ja) 1999-06-15
US20020028927A1 (en) 2002-03-07
EP0853627A4 (en) 1998-10-07
IL149971A (en) 2010-04-29
JP2007269812A (ja) 2007-10-18
HUP9802662A2 (hu) 1999-05-28
KR100416335B1 (ko) 2004-07-27
KR19990022104A (ko) 1999-03-25
CA2223140A1 (en) 1996-12-12
NO310239B1 (no) 2001-06-11
US6184366B1 (en) 2001-02-06
NO975644L (no) 1998-02-04
CA2223140C (en) 2008-08-05
ES2214543T3 (es) 2004-09-16
US5750664A (en) 1998-05-12
EP0853627B1 (en) 2004-01-21
CN1192216A (zh) 1998-09-02
DE69631376D1 (de) 2004-02-26
MX9709502A (es) 1998-10-31
US5681824A (en) 1997-10-28
NZ312299A (en) 1999-08-30
TW366345B (en) 1999-08-11
US20080214802A1 (en) 2008-09-04
IL122251A0 (en) 1998-04-05
HU221342B1 (en) 2002-09-28
AU707779B2 (en) 1999-07-22
RU2170738C2 (ru) 2001-07-20
AU6380296A (en) 1996-12-24
JP4009318B2 (ja) 2007-11-14

Similar Documents

Publication Publication Date Title
EP0853627B1 (en) Substituted liposaccharides useful in the treatment and prevention of endotoxemia
EP1248629B1 (en) Prevention and treatment of pulmonary bacterial infection or symptomatic pulmonary exposure to endotoxin by inhalation of antiendotoxin drugs
JP3865411B2 (ja) 抗−エンドトキシン化合物
US5952309A (en) Method for treating alcoholic liver disease
WO1997011708A9 (en) Method for treating alcoholic liver disease
JP2000511916A (ja) ポリオールスクシネートおよびその医薬製剤
HK1051490B (en) Prevention and treatment of pulmonary bacterial infection or symptomatic pulmonary exposure to endotoxin by inhalation of antiendotoxin drugs
JPWO2011065480A1 (ja) 神経細胞死抑制剤
HK1020333A (en) Polyol succinates and their pharmaceutical formulation

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE PROPOSED AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 20010504

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS WAS NOTIFIED IN THE OFFICIAL JOURNAL DATED 20010607